Research Reports Initiation on Biotech Stocks -- La Jolla Pharma, Spectrum Pharma, Advaxis, and Aevi Genomic

Monday, April 10, 2017 Research News
Email Print This Page Comment bookmark
Font : A-A+

NEW YORK, April 10, 2017 /PRNewswire/ --

Focus is on the Biotech space, which was off to a hot start in 2017. However,

since March 15th, 2017, it has been the worst performing sector, down nearly 5%, as per an article on Investopedia. Pre-market, Stock-Callers.com scans the performances of La Jolla Pharmaceutical Co. (NASDAQ:
LJPC), Spectrum Pharmaceuticals Inc. (NASDAQ: SPPI), Advaxis Inc. (NASDAQ: ADXS), and Aevi Genomic Medicine Inc. (NASDAQ: GNMX). Learn more about these stocks by downloading their free report at:

http://stock-callers.com/registration

La Jolla Pharma  

Last Friday, San Diego, California headquartered La Jolla Pharmaceutical Co.'s stock dropped 2.14%, to close the day at $26.94. A total volume of 458,077 shares was traded. The Company's shares have surged 30.02% in the previous three months and 53.68% on an YTD basis. The stock is trading 27.40% above its 200-day moving average. Additionally, shares of La Jolla Pharma, which focuses on the discovery, development, and commercialization of therapeutics for life-threatening diseases, have a Relative Strength Index (RSI) of 37.34. The free research report on LJPC is available at:

http://stock-callers.com/registration/?symbol=LJPC

Spectrum Pharma  

Shares in Henderson, Nevada headquartered Spectrum Pharmaceuticals Inc. rose 0.65%, finishing Friday's session at $6.20. The stock recorded a trading volume of 586,040 shares. The Company's shares have gained 2.31% in the last month, 28.90% over the previous three months, and 39.95% since the start of this year. The stock is trading above its 50-day and 200-day moving averages by 4.09% and 16.83%, respectively. Furthermore, shares of Spectrum Pharma, which develops and commercializes oncology and hematology drug products, have an RSI of 48.69.

On April 04th, 2017, Spectrum Pharmaceuticals announced the presentation of preclinical data of ROLONTIS from a poster presentation session at the American Association for Cancer Research Annual Meeting. The complimentary report on SPPI can be downloaded at: http://stock-callers.com/registration/?symbol=SPPI

Advaxis  

Princeton, New Jersey-based Advaxis Inc.'s stock finished 0.77% higher at $7.84 last Friday at the close. A total volume of 420,735 shares was traded. The Company's shares have advanced 9.50% on an YTD basis. The stock is trading below its 50-day moving average by 9.52%. Additionally, shares of Advaxis, which focuses on the discovery, development, and commercialization of Lm-LLO cancer immunotherapies in the US, have an RSI of 40.34.

On March 27th, 2017, Advaxis announced that the Company published online a poster previously presented at the National Cancer Research Institute Cancer Conference in Liverpool that showed axalimogene filolisbac achieved durable response in a patient with persistent or recurrent metastatic carcinoma of the cervix (PRmCC). The Company is preparing to initiate a phase-3 trial in PRmCC later this year. Visit us today and download our complete research report on ADXS for free at:

http://stock-callers.com/registration/?symbol=ADXS

Aevi Genomic  

Wayne, Pennsylvania-based Aevi Genomic Medicine Inc.'s shares ended the session flat at $1.69, with a total trading volume of 325,104 shares. The stock is trading 58.83% below its 50-day moving average. Shares of the Company, which engages in the research and development of products in the field of biotechnology and associated medical equipment in the US, have an RSI of 26.51.

On March 20th, 2017, Aevi Genomic Medicine announced top-line results from the SAGA trial of AEVI-001 (oral non-stimulant) in adolescents with mGluR mutation positive (mGluR+) ADHD. AEVI-001 represents a novel paradigm of genomic diagnosis and treatment in neuropsychiatric disorders. 

On March 21st, 2017, research firm Needham reiterated its 'Buy' rating on the Company's stock with a decrease of the target price from $12 a share to $9 a share. Get free access to your technical report on GNMX at:

http://stock-callers.com/registration/?symbol=GNMX

--

Stock Callers: 

Stock Callers (SC) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and micro-cap stocks. SC has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below. 

SC has not been compensated; directly or indirectly; for producing or publishing this document. 

PRESS RELEASE PROCEDURES:

The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third party research service company (the "Reviewer") represented by a credentialed financial analyst [for further information on analyst credentials, please email [email protected]. Rohit Tuli, a CFA® charterholder (the "Sponsor"), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by SC. SC is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.  

NO WARRANTY 

SC, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. SC, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, SC, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice. 

NOT AN OFFERING 

This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither SC nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit

http://stock-callers.com/legal-disclaimer/

CONTACT For any questions, inquiries, or comments reach out to us directly. If you're a company we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at: Email: [email protected] Phone number:  +44-330-808-3765 Office Address: Clyde Offices, Second Floor, 48 West George Street, Glasgow, U.K. -G2 1BP

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

SOURCE Chelmsford Park SA



Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions

News A - Z

A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

News Search

Medindia Newsletters

Subscribe to our Free Newsletters!

Terms & Conditions and Privacy Policy.

Find a Doctor

Press Release Category

Press Release Archive

Stay Connected

  • Available on the Android Market
  • Available on the App Store